Top Markets
Coin of the day
Ambrx Biopharma Inc. Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAM
주식 순위 #6975
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused... Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
주가
$28.00
마지막 동기화: 2024-03-06
시가총액
$1.77B
변동 (1일)
0.07%
변동 (1년)
0.00%
국가
US
거래 Ambrx Biopharma Inc. (AMAM)

카테고리

Ambrx Biopharma Inc. (AMAM)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Ambrx Biopharma Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Ambrx Biopharma Inc.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH